Member Info for wozzer70

Volume Velocity: Nearly 50 trades so far today, with notable "Unknown" (likely institutional/block) and "Buy" prints.

Institutional Positioning: Significant blocks of 200,000 (8.67p), 203,720 (8.25p), and 119,047 (8.40p) suggest smart money is positioning ahead of the Guident catalyst.

Price Resilience: Today’s volume is transacting between 8.45p and 8.70p. The 8p floor hasn't been tested.

The Logic: Large trades at 8.70p, nearly 10% above the placing price, indicate institutional confidence and belief that the SEC Effectiveness notice is close. The "de-risking" phase is nearing completion.

The Path to a Very Different Tek!

The filings tell you where we are; the monetisation and compounding will decide where we go. My thesis is simple: listed assets + disciplined monetisation + occasional special returns creates a very different Tek from the one people remember. This Tek is one that will compound value, reward shareholders, and has multiple revenue streams for long-term growth.

As Tekcapital's portfolio matures and with Guident's IPO on the horizon, it may be worth considering the possibility of a share consolidation and US listing in the near future. Reducing the share count could attract a broader pool of institutional investors, and with most of Tek's assets now US-listed, a US listing for the parent company could create stronger market visibility. If Tek wants to unlock the full value of its portfolio, these steps make a lot of sense. Just something to keep on the radar. DYOR

Stage 1: Notice of Effectiveness (Form EFFECT)

The SEC confirms the 17th February "staleness" hurdle is cleared. This is the crucial "Green Light" that allows the sale of shares to begin and triggers a potential Tekcapital (TEK) rerate as the final administrative barrier falls.

Stage 2: Final Pricing (Form 424B4)

Within 24-48 hours of effectiveness, the underwriters (Dominari/Prime Number Capital) will set the exact IPO price. This replaces the indicative $4–$5 range with a final, fixed offering price.

Stage 3: Nasdaq "Go-Live"

Guident will appear on the Nasdaq IPO calendar and begin trading under ticker $GDNT. This typically occurs within one business day after final pricing is confirmed.

Stage 4: Institutional Re-Rating

With $GDNT now liquid and tradable, Tekcapital’s stake is mark-to-market, offering real-time valuation transparency. This will provide the foundation to bridge the gap toward the estimated 30p+ NAV post-IPO, attracting larger institutional interest.

Guident Update: The S-1/A is live, and terms are set. While the exact date is at the discretion of the SEC and underwriters, a February “push” is the logical move, as the current financials are valid.

Tekcapital’s Position: Tek enters this window with a record NAV, lower OPEX, and a fresh £1.5m cash injection from the recent placing. The portfolio now includes liquid, listed assets (MicroSalt, Lucyd, GenIP) providing real-time transparency.

Upside Potential: If Guident lists successfully, a rerate for Tek is likely, driven by (a) visible value of the $GDNT stake, (b) potential $4.5m convertible repayment, and (c) ongoing monetisation options for its listed assets.

Risk – Timing: If the effectiveness window slips and requires a financial refresh, it’s a delay, not a collapse. The value drivers (NAV, AI pivot, listed assets) remain intact; sentiment may dip until a new timetable is set.

Bottom Line: The recent placing is a strategic refuel ahead of the Guident catalyst, not a red flag. The path to value remains intact; the key risk is timing, not fundamentals. DYOR.

While some focus on board noise, the tape tells the real story. Today’s 8m+ volume -including a 2.05m share block at 8.725p -shows institutional hands loading up on Tekcapital. The 'Coiled Spring' is real.

We’re now in the final administrative sprint before the 17th Feb SEC deadline, which could bridge the gap to the 26p audited NAV. The 'mystery' ends when the effectiveness notice hits. If the pros are absorbing millions of shares at a premium to the placing price, timing is everything.

The stage is set ✨ DYOR.

Looking at today’s RNS, it’s easy to get caught up in the 8p placing. I get it- it feels like a curveball. But when you step back and connect the dots, the logic becomes clear.

Tekcapital isn’t raising capital for survival; this is a Strategic Injection backed by CMC Markets. Think of it like a professional pit stop mid-race. Management is strengthening the balance sheet specifically for the Generative AI pivot and ensuring we have the 'dry powder' needed as we enter the Guident IPO window.

While the short-term noise focuses on the 8p entry, the big picture is about Institutional Positioning. Securing this funding now, just days before the 17th Feb SEC deadline, ensures the 'administrative sprint' is fully fueled.

This isn't the finish line; it’s the setup for the Liquidity Phase. Today’s 8p floor is the immediate reality, but the 26p audited NAV remains the destination. The pieces are falling into place, and the road ahead will look very different once the $GDNT ticker is live. DYOR ✨

Good point, ddubya. This liquidity injection is the final 'fuel' for the Generative AI pivot and the Guident IPO. The difference now is that a powerhouse like CMC Markets is providing the clarity. Timing is everything, strengthening the balance sheet now ensures the 'full picture' is ready for the 17th Feb deadline.

It’s about Effectiveness, not just the 'Float' date.

The 17th Feb is the SEC 'Staleness' deadline for the current filings. Meeting this window avoids a costly 2025 re-audit and months of delay. Whether the first trade is the 17th or the 19th is noise; the SEC Green Light (EFFECT) is the structural catalyst that bridges the gap between this 8p institutional floor and the 26p audited NAV.

The pros at CMC Markets clearly like the timing at 8p. The math hasn't changed.

If the EFFECT notice drops this week, the £1.5m placing at 8p will look like a masterstroke of bottom-fishing in hindsight. While the discount is the immediate focus, the backing of a powerhouse like CMC Markets changes the narrative from 'desperation' to 'strategic positioning'.

Management is clearly front-loading capital for the Generative AI pivot before the 17th Feb deadline unlocks the Guident revaluation. Strengthening the balance sheet now ensures Tek is ready for the 'Liquidity Phase' with a full tank of air. Once $GDNT goes live, 8p will likely be remembered as the missed opportunity of 2026.

CMC Markets & The Strategic Pivot: Looking Beyond the 8p Noise ⚖️

The 10th Feb RNS raising £1.5m at 8p has caught the board by surprise just days before the 17th Feb Guident deadline. While the timing is unexpected, the involvement of CMC Markets-a FTSE 250-level powerhouse-changes the narrative. CMC doesn't back 'survival' raises; they back growth stories.

By strengthening the balance sheet specifically for Generative AI opportunities, Tekcapital is clearly priming a new growth engine. If the pros at CMC are happy to lock in at 8p ahead of the Guident news, the 'dilution' noise from the sidelines starts to look like a missed institutional opportunity.

The 26p audited NAV remains the long-term target, but the 8p floor is now the immediate market reality. We look for management transparency on this new AI venture, but the 'Liquidity Phase' catalyst with $GDNT remains the imminent bridge to that NAV.

The raising of £1.5m just days before the 17th Feb Guident deadline has caught many by surprise. While Tekcapital’s long-term transition to a "Self-Funding" ecosystem remains the ultimate goal, this unexpected placing suggests a pivot towards Generative AI, which could have strategic merit. However, the timing leaves many of us questioning why now, especially at a discount.

We, as shareholders, are looking for transparency. If the portfolio is maturing, and with Guident’s IPO on the horizon, why raise funds now at a discount? The answer might lie in the mention of new portfolio companies in the RNS - is this funding for a new growth engine? The $GDNT listing could provide liquidity, but this raise ahead of such a key event feels like a move to position Tek for future growth, potentially in an AI-driven market.

While the 26p NAV remains the long-term target, it’s clear that the 8p price is now the immediate reality. The market will want further insight into the rationale behind this placing - particularly its impact on the portfolio's evolving strategy. We need clarity from management on this pivotal shift.

The era of dilution is closing; the era of monetisation is opening. With four public engines (SALT, LUCY, GNIP, GDNT), Tekcapital is becoming a self-sustaining ecosystem. We’ve built the fleet - now we watch them sail. The re-rate is just the beginning.

The market currently discounts Tekcapital because our largest assets were 'locked' in private wrappers. The 17th February is the key. When the $GDNT ticker goes live, the 'Private-to-Public' discount has no place left to hide. We’re moving from estimated value to audited market reality. 🗝️

It is fascinating to observe the reaction when deep-dive research meets a stagnant share price. On many boards, providing a consistent framework of audited data (NAV, SEC filings, and IPO deadlines) is often mislabelled as 'ramping.'

In reality, 'ramping' is hype without substance. Conversely, due diligence is the repetitive application of facts to a valuation gap. When a stock trades at a 60% discount to its 26p audited NAV, the repetition of that fact isn't for the benefit of the poster - it's a record of the disconnect.

As we approach the 17th February milestone, the board will naturally split into two camps:

Those focusing on the person posting.

Those focusing on the portfolio value.

I have no interest in the former. I am here exclusively for the latter. The transition from private incubation to a public liquidity phase is a complex process that requires constant tracking. If that depth of data is 'too much' for some, the filter button is a useful tool. For the rest, the numbers remain the only objective truth.

If you're tracking the fundamentals, the current disconnect between price and value is mathematically undeniable. Tekcapital’s NAV is around 26p per share (according to the latest audits), while the share price sits at ~10p. That’s a 60% discount.

The Guident IPO isn’t just a new ticker; it’s a revaluation event. A successful listing at projected levels could push NAV to 32p per share. This is the end of the 'venture capital' phase. Tekcapital is now a diversified holding company with transparent, market-set valuations.

MicroSalt

Innovative Eyewear

GenIP

And soon Guident…

The market’s focus on the 10p share price is noise. The focus on the 26p-32p NAV is what matters. The 17th February deadline marks the bridge between the two.

Keep your eyes on the real numbers - the transition is happening. ✨

Many investors are still missing the transition happening at Tekcapital. For years, Tek has been in the 'incubation phase', focusing on deploying capital into private university IP. That phase is complete. Now, with Guident (GDNT), MicroSalt, Innovative Eyewear, and GenIP, Tekcapital is stepping into the Liquidity Phase - a fully diversified holding company with public growth engines.

The numbers:

NAV validation is coming as the public market starts setting the price for Tek’s largest assets.

No more “estimates”; listed assets mean real market value is being set now.

Self-sustaining: With listed holdings, Tek now has capital levers to fund growth without dilution.

The disconnect: with a current NAV of ~26p and the share price at ~10p, the math is staring the market in the face.

The 17th February IPO isn’t just a date; it’s the moment when the 'Private-to-Public' discount begins to disappear. The research is clear - this transition is happening. ✨

The Guident IPO is almost here, and the potential is enormous. If Guident manages to hit anywhere near a anticipated $100 million valuation, we could see a re-rate of Tekcapital’s NAV far bigger than many are expecting. It’s a high-stakes moment, and the pressure of the unknown adds a layer of excitement - because the upside here is not just about the IPO day; it’s about what comes after. Tek is on the edge of something huge, and the next few weeks could redefine everything.

The excitement isn't just about the opening bell; it’s about the "New Tek" that emerges afterward - a company with a fully monetised portfolio and the capital to compound growth for years. We are on the edge of a major transition. Get ready. ✨

The Final Countdown: Guident IPO!

With the Guident IPO targeted for completion before the 17th February fiscal deadline, we are entering a pivotal week for Tekcapital.

This isn't just a listing; it is the moment the market recognises the true value of what Tek has been building. We are moving from a period of portfolio development into a phase of active monetisation and long-term compounding growth.

The runway is clear - The stage is set.

Guident’s IPO is the key catalyst for Tekcapital’s rerate. A successful Nasdaq listing will put a clear market value on Tek’s largest private holding and help close the gap between a ~US$77m NAV and a much lower market cap.

That’s only the start. With a listed Guident, Tek has more options: potential repayment of the US$4.5m convertible, the ability to trim stakes over time, and capital to recycle into the next wave of portfolio growth. Monetisation plus disciplined reinvestment is how the NAV has already compounded from c.US$33m to US$77.4m, and it’s how long‑term value creation can continue from here.